1999
DOI: 10.2165/00003088-199937002-00008
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Multiple Cilostazol Doses on Single Dose Lovastatin Pharmacokinetics in Healthy Volunteers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
9
0

Year Published

2001
2001
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 5 publications
1
9
0
Order By: Relevance
“…Thus, a reduction in the dose of cilostazol to 50 mg, twice a day, should be considered during coadministration of inhibitors of these cytochrome enzymes (64,65). No dosage adjustments are necessary for drugs metabolized by CYP3A4, such as lovastatin (3). Coadministration of a single 25-mg dose of warfarin with a twice daily 100-mg dose of cilostazol does not alter (R) and (S)-warfarin pharmacokinetics, prothrombin time, partial thromboplastin time, Ivy bleeding times, or cilostazol protein binding (36).…”
Section: Pharmacokineticsmentioning
confidence: 99%
“…Thus, a reduction in the dose of cilostazol to 50 mg, twice a day, should be considered during coadministration of inhibitors of these cytochrome enzymes (64,65). No dosage adjustments are necessary for drugs metabolized by CYP3A4, such as lovastatin (3). Coadministration of a single 25-mg dose of warfarin with a twice daily 100-mg dose of cilostazol does not alter (R) and (S)-warfarin pharmacokinetics, prothrombin time, partial thromboplastin time, Ivy bleeding times, or cilostazol protein binding (36).…”
Section: Pharmacokineticsmentioning
confidence: 99%
“…In Italy, lovastatin was introduced in 2005, based on the present bioequivalence study. In view of the number of subjects enrolled for the present investigation, which is the highest among those available in literature for kinetic studies (11)(12)(13)(14)(15)(16)(17), and of the interesting aspects emerging in terms of lovastatin pharmacokinetics, we have decided to publish the present study. This work has evaluated the bioequivalence of an oral formulation of lovastatin 40 mg tablets (lovastatin generic or LVSG), in comparison with the reference MSD product Mevinacor ® 40 mg tablets by assessing plasma levels of lovastatin and lovastatin hydroxyacid.…”
Section: Introductionmentioning
confidence: 99%
“…Bramer et al . reported that the concentration of lovastatin and its β‐hydroxy acid metabolite, CYP3A substrate, was increased by up to twofold after multiple co‐administrations of cilostazol . This suggests that cilostazol or its metabolites might have a mild inhibitory effect on CYP3A.…”
Section: Discussionmentioning
confidence: 99%